Laquinimod protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model

Abstract Background The oral immunomodulatory agent laquinimod is currently evaluated for multiple sclerosis (MS) treatment. Phase II and III studies demonstrated a reduction of degenerative processes. In addition to anti-inflammatory effects, laquinimod might have neuroprotective properties, but it...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Anna T. Wilmes, Sabrina Reinehr, Sandra Kühn, Xiomara Pedreiturria, Laura Petrikowski, Simon Faissner, Ilya Ayzenberg, Gesa Stute, Ralf Gold, H. Burkhard Dick, Ingo Kleiter, Stephanie C. Joachim
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	BMC 2018-06-01
Ráidu:	Journal of Neuroinflammation
Fáttát:	Multiple sclerosis Laquinimod EAE Optic nerve Inflammation Demyelination
Liŋkkat:	http://link.springer.com/article/10.1186/s12974-018-1208-3
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!